Strathspey Crown and the first Medicare-Medicaid opt-out company in medtech | A conversation with Robert Grant

December 3, 2012 by Brian Johnson

In this MassDevice Big 100 West preview, we talk to Strathspey Crown Chairman Robert Grant about how his private equity firm Strathspey Crown is looking to break the mold.

Strathspey Crown CEO Robert Grant

If Robert Grant is successful – a good bet, judging by his track record – 1 day his new venture, private equity firm Strathspey Crown, will be known as a leader in the nascent field of "lifestyle medicine."

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

The special sauce in contract research organization Ora Inc.'s recipe for ophthalmology trials is the eye care practice its founder started 30 years ago.

Animal rights advocacy group PETA holds a tiny stake in several medtech companies, taking frequent advantage of its shareholder rights to push changes in the way device makers experiment on animals.

AliveCor's interim-ish CEO Euan Thomson talks about the data-driven future, why he jumped ship at Accuray and how to navigate the intersection between the tempered medical device world and the wanton nimbleness of Silicon Valley.

Medtronic executive Dr. Stephen Oesterle thinks Google will be a force to be reckoned with in the medical technology space in coming years.

Roger Pontz, 1 of the first recipients of Second Sight Medical's Argus II 'bionic eye,' tells MassDevice.com about how it's changed his life.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp